» Articles » PMID: 38048807

Alteration of Circulating MiRNAs During Myocardial Infarction and Association with Lipid Levels

Overview
Journal Lab Med
Date 2023 Dec 4
PMID 38048807
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Increasing mortality and morbidity of coronary artery disease (CAD) highlight the emerging need for novel noninvasive markers such as circulating microRNAs (miRNAs).

Objective: To evaluate the circulating levels of miR-126-3p, miR-210-3p, let-7g-5p, and miR-326, and their associations with known contributors to CAD, in CAD subgroups.

Methods: We divided the cohort into 4 groups: non-CAD controls (≤30% stenosis; n = 55), and patients with stable angina pectoris (SAP; n = 48), unstable AP (UAP; n = 46), and myocardial infarction (MI; n = 36). The circulating levels of miR-126-3p, miR-210-3p, let-7g-5p, and miR-326 were determined using TaqMan Advanced miRNA Assays in serum specimens.

Results: Circulating miR-126-3p levels were lower in the MI and UAP groups, compared with the non-CAD group, whereas miR-210-3p circulating levels were lower in the MI group than others. The levels of circulating let-7g-5p were shown to be useful for distinguishing UAP from MI, and there were substantial differences in circulating let-7g-5p levels between the UAP and MI groups. Moreover, lipid levels and ratios were lower in individuals with high circulating miR-126-3p and miR-210-3p levels.

Conclusions: The study results suggest that circulating miR-126-3p, miR-210-3p, and let-7g-5p are differentiated between different clinical presentations of CAD and associated with lipid levels, which are important risk factors and determinants of CAD.

Citing Articles

miRNAs and Hematological Markers in Non-Alcoholic Fatty Liver Disease-A New Diagnostic Path?.

Michalak A, Guz M, Kozicka J, Cybulski M, Jeleniewicz W, Telejko I Biomedicines. 2025; 13(1).

PMID: 39857813 PMC: 11762403. DOI: 10.3390/biomedicines13010230.


Mitochondrial microRNAs: New Emerging Players in Vascular Senescence and Atherosclerotic Cardiovascular Disease.

Canale P, Borghini A Int J Mol Sci. 2024; 25(12).

PMID: 38928325 PMC: 11204228. DOI: 10.3390/ijms25126620.

References
1.
Zhelankin A, Stonogina D, Vasiliev S, Babalyan K, Sharova E, Doludin Y . Circulating Extracellular miRNA Analysis in Patients with Stable CAD and Acute Coronary Syndromes. Biomolecules. 2021; 11(7). PMC: 8301961. DOI: 10.3390/biom11070962. View

2.
Wang S, Aurora A, Johnson B, Qi X, McAnally J, Hill J . The endothelial-specific microRNA miR-126 governs vascular integrity and angiogenesis. Dev Cell. 2008; 15(2):261-71. PMC: 2685763. DOI: 10.1016/j.devcel.2008.07.002. View

3.
Vejnar C, Zdobnov E . MiRmap: comprehensive prediction of microRNA target repression strength. Nucleic Acids Res. 2012; 40(22):11673-83. PMC: 3526310. DOI: 10.1093/nar/gks901. View

4.
Fish J, Santoro M, Morton S, Yu S, Yeh R, Wythe J . miR-126 regulates angiogenic signaling and vascular integrity. Dev Cell. 2008; 15(2):272-84. PMC: 2604134. DOI: 10.1016/j.devcel.2008.07.008. View

5.
Sun X, Sit A, Feinberg M . Role of miR-181 family in regulating vascular inflammation and immunity. Trends Cardiovasc Med. 2013; 24(3):105-12. PMC: 3943593. DOI: 10.1016/j.tcm.2013.09.002. View